Table 1.
Characteristics of studies included in Meta-analysis of overall MS
| Study author | Year | Country | Ethnicity | Sex cases/controls | Total cases/control | Age case/control (Mean) | Genotyping method | Quality score |
|---|---|---|---|---|---|---|---|---|
| FokI (rs2228570) | ||||||||
| Partridge et al. | 2004 | UK | European | M = NR F=NR | 406 /234 | 43.8 ± 11.2 / 50.1 | NR | 7 |
| Tajouri et al. | 2005 | Australia | Australian | M = NR F=NR | 98 / 93 | NR | PCR–RFLP | 6 |
| Smolders et al. | 2009 | Netherland | European | M = 62/ 142 F = 150/ 147 | 212 / 289 | 46.7 ± 11.9 /34.9 ± 14.3 | PCR–RFLP | 8 |
| Dickinson et al. | 2009 | Australia | Australian | M = NR F=NR | 136 / 235 | 43.5 ± 9.3/ 43.6 ± 9.2 | Taq-Man | 7 |
| Simon et al. | 2010 | USA | American | M = NR F=NR | 100 / 100 | NR | Taq-Man | 7 |
| Garcia-Martin et al. | 2013 | Spain | European | M = 94/ 98 F = 209/ 212 | 303 / 310 | 43.9 ± 11.4/ 43.4 ± 11.7 | Taq-Man | 8 |
| Al-Temaimi et al. | 2015 | Kuwait | Asian | M = 17/ 19 F = 33/ 31 | 50 / 50 | 33.4 ± 9.6/ 28.6 ± 7.9 | Taq-Man | 7 |
| Narooie-Nejad et al. | 2015 | Iran | Asian | M = 25 / 28 F = 88/ 94 | 113 / 122 | 32.4 ± 8.9/ 30.8 ± 10.2 | PCR–RFLP | 7 |
| Cierny et al. | 2015 | Slovakia | European | M = 66 / 74 F = 204 / 229 | 270 / 303 | 41.3 ± 10.8/ 38.7 ± 13.6 | PCR–RFLP | 8 |
| Luisa Agnello et al. | 2016 | Italy | European | M = 24 / 30 F = 80 / 42 | 104 / 75 | 39.6 ± 10.3/ 45.2 ± 9.36 | PCR–RFLP | 6 |
| Abdollahzadeh et al. | 2016 | Iran | Asian | M = 40 / 38 F = 120 / 112 | 160 / 150 | 35.9 ± 3 / 36.8 ± 1.8 | PCR–RFLP | 7 |
| Yucel et al. | 2017 | Turkey | European | M = NRF=NR | 29 / 114 | 33.7 ± 10.7 / 33.1 ± 8.5 | Taq-Man | 6 |
| Bettencourt et al. | 2017 | Portugal | European | M = 185/198 F = 348/248 | 533 / 446 | 30.2 ± 9.3/ NR | Taq-Man | 8 |
| Kamisli et al. | 2018 | Turkey | European | M = 46 / 58 F = 121 / 88 | 167 / 146 | 39.96 ± 9.4 / 33.81 ± 7.1 | Taq-Man | 7 |
| Sadeghi et al. | 2018 | Iran | Asian | M = 17/11 F = 63/39 | 80 / 50 | 18–60/ 18–60 | PCR–RFLP | 6 |
| Křenek et al. | 2018 | Czech Republic | European | M = 80/49 F = 216/86 | 296/135 | 34–37 / NR | PCR–RFLP | 7 |
| TaqI (rs731236) | ||||||||
| Partridge et al. | 2004 | UK | European | M = NR F=NR | 402 /231 | 43.8 ± 11.2 / 50.1 | NR | 7 |
| Tajouri et al. | 2005 | Australia | Australian | M = NR F=NR | 104 / 186 | NR | PCR–RFLP | 6 |
| Smolders et al. | 2009 | Netherland | European | M = 62/ 142 F = 150/ 147 | 212 / 289 | 46.7 ± 11.9 /34.9 ± 14.3 | PCR–RFLP | 8 |
| Dickinson et al. | 2009 | Australia | Australian | M = NR F=NR | 136 / 235 | 43.5 ± 9.3/ 43.6 ± 9.2 | Taq-Man | 7 |
| Simon et al. | 2010 | USA | American | M = NR F=NR | 100 / 100 | NR | Taq-Man | 7 |
| Sioka et al. | 2011 | Greece | European | M = 23/ 23 F = 46/ 58 | 69 / 81 | 39 ± 10.5/38.7 ± 10.7 | Taq-Man | 7 |
| Agliardi et al. | 2011 | Italy | European | M = NR F=NR | 641 / 558 | 27.8 ± 9.2/ 29.4 ± 6.5 | Taq-Man | 8 |
| Irizar et al. | 2012 | Spain | European | M = NR F=NR | 136 / 337 | 44.14 ± 13.02/ 50.17 ± 13.26 | PCR-SSP | 7 |
| Garcia-Martin et al. | 2013 | Spain | European | M = 94/ 98 F = 209/ 212 | 303 / 310 | 43.9 ± 11.4/ 43.4 ± 11.7 | Taq-Man | 8 |
| Selma et al. | 2015 | Tunisia | African | M = 22/ 47 F = 38/ 67 | 60 / 114 | 35.8 ± 6.3 / 37 ± 9.3 | PCR–RFLP | 6 |
| Narooie-Nejad et al. | 2015 | Iran | Asian | M = 25 / 28 F = 88/ 94 | 113 / 122 | 32.4 ± 8.9/ 30.8 ± 10.2 | PCR–RFLP | 7 |
| Al-Temaimi et al. | 2015 | Kuwait | Asian | M = 17/ 19 F = 33/ 31 | 50 / 50 | 33.4 ± 9.6/ 28.6 ± 7.9 | Taq-Man | 7 |
| Yamout et al. | 2016 | Lebanon | Asian | M = NR F=NR | 50 / 99 | 32.3 ± 12.7 / 35.2 ± 13 | PCR–RFLP | 6 |
| Cierny et al. | 2016 | Slovakia | European | M = 66 / 74 F = 204 / 229 | 270 / 303 | 41.3 ± 10.8/ 38.7 ± 13.6 | PCR–RFLP | 8 |
| Luisa Agnello et al. | 2016 | Italy | European | M = 24 / 30 F = 80 / 42 | 104 / 75 | 39.6 ± 10.3/ 45.2 ± 9.36 | PCR–RFLP | 6 |
| Terzi et al. | 2016 | Turkey | European | M = NR F=NR | 87 / 99 | 30.14 9.66/ NR | PCR–RFLP | 6 |
| Abdollahzadeh et al. | 2016 | Iran | Asian | M = 40 / 38 F = 120 / 112 | 160 / 150 | 35.9 ± 3 / 36.8 ± 1.8 | PCR–RFLP | 7 |
| Yucel et al. | 2017 | Turkey | European | M = NR F=NR | 28 / 72 | 33.7 ± 10.7 / 33.1 ± 8.5 | Taq-Man | 6 |
| Kamisli et al. | 2018 | Turkey | European | M = 46 / 58 F = 121 / 88 | 167 / 146 | 39.96 ± 9.4 / 33.81 ± 7.1 | Taq-Man | 7 |
| Morales et al. | 2018 | Mexico | American | M = 39/ 57 F = 81/123 | 120 / 180 | 33.89 ± 10.03/ 32.79 ± 10.17 | Taq-Man | 6 |
| Sadeghi et al. | 2018 | Iran | Asian | M = 17/11 F = 63/39 | 80 / 50 | 18–60/ 18–60 | PCR–RFLP | 6 |
| Cakina et al.. | 2018 | Turkey | European | M = 19/22 F = 51/48 | 70 / 70 | 44.4 ± 11.2 / 38.2 ± 9.5 | PCR–RFLP | 7 |
| Křenek et al. | 2018 | Czech Republic | European | M = 80/49 F = 216/86 | 296 / 135 | 34–37 / NR | PCR–RFLP | 7 |
| BsmI (rs1544410) | ||||||||
| Fukazawa et al. | 1999 | Japan | Asian | M = 21/33 F = 56/62 | 77 / 95 | 34.9 ± 12.9/NR | PCR–RFLP | 8 |
| Qinli Sun et al. | 2004 | China | Asian | M = NR F=NR | 63 / 95 | NR | PCR–RFLP | 6 |
| Bing Wu et al. | 2009 | China | Asian | M = NR F=NR | 83 / 120 | NR | PCR–RFLP | 7 |
| Simon et al. | 2010 | USA | American | M = NR F=NR | 101 / 100 | NR | Taq-Man | 7 |
| Sioka et al. | 2011 | Greece | European | M = 23/ 23 F = 46/ 58 | 69 / 81 | 39 ± 10.5/38.7 ± 10.7 | Taq-Man | 7 |
| Al-Temaimi et al. | 2015 | Kuwait | Asian | M = 17/ 19 F = 33/ 31 | 50 / 50 | 33.4 ± 9.6/ 28.6 ± 7.9 | Taq-Man | 7 |
| Narooie-Nejad et al. | 2015 | Iran | Asian | M = 25 / 28 F = 88/ 94 | 113 / 122 | 32.4 ± 8.9/ 30.8 ± 10.2 | PCR–RFLP | 7 |
| Abdollahzadeh et al. | 2016 | Iran | Asian | M = 40 / 38 F = 120 / 112 | 160 / 150 | 35.9 ± 3 / 36.8 ± 1.8 | PCR–RFLP | 7 |
| Yamout et al. | 2016 | Lebanon | Asian | M = NR F=NR | 50 / 99 | 32.3 ± 12.7 / 35.2 ± 13 | PCR–RFLP | 6 |
| Cierny et al. | 2016 | Slovakia | European | M = 66 / 74 F = 204 / 229 | 270 / 303 | 41.3 ± 10.8/ 38.7 ± 13.6 | PCR–RFLP | 8 |
| Luisa Agnello et al. | 2016 | Italy | European | M = 24 / 30 F = 80 / 42 | 104 / 75 | 39.6 ± 10.3/ 45.2 ± 9.36 | PCR–RFLP | 6 |
| Terzi et al. | 2016 | Turkey | European | M = NR F=NR | 87 / 100 | 30.14 ± 9.66/ NR | PCR–RFLP | 6 |
| Morales et al. | 2017 | Mexico | American | M = 39/ 57 F = 81/123 | 120 / 180 | 33.89 ± 10.03/ 32.79 ± 10.17 | Taq-Man | 6 |
| Sadeghi et al. | 2018 | Iran | Asian | M = 17/11 F = 63/39 | 80 / 50 | 18–60/ 18–60 | PCR–RFLP | 6 |
| Cakina et al.. | 2018 | Turkey | European | M = 19/22 F = 51/48 | 70 / 70 | 44.4 ± 11.2 / 38.2 ± 9.5 | PCR–RFLP | 7 |
| Křenek et al. | 2018 | Czech Republic | European | M = 80/49 F = 216/86 | 296 / 135 | 34–37 / NR | PCR–RFLP | 7 |
| ApaI (rs7975232) | ||||||||
| Niino et al. | 2000 | Japan | Asian | M = 21 / 33 F = 56 / 62 | 77 / 95 | 36.2 ± 11.2 / 34.4 ± 10.2 | PCR–RFLP | 7 |
| Qinli Sun et al. | 2004 | China | Asian | M = NR F=NR | 63 / 95 | NR | PCR–RFLP | 6 |
| Tajouri et al. | 2005 | Australia | Australian | M = NR F=NR | 104 / 100 | NR | PCR–RFLP | 6 |
| Smolders et al. | 2009 | Netherland | European | M = 62/ 142 F = 150/ 147 | 212 / 289 | 46.7 ± 11.9 /34.9 ± 14.3 | PCR–RFLP | 8 |
| Bing Wu et al. | 2009 | China | Asian | M = NR F=NR | 83 / 120 | NR | PCR–RFLP | 7 |
| Simon et al. | 2010 | USA | American | M = NR F=NR | 100 / 100 | NR | Taq-Man | 7 |
| Irizar et al. | 2012 | Spain | European | M = NR F=NR | 134 / 340 | 44.14 ± 13.02/ 50.17 ± 13.26 | PCR-SSP | 7 |
| Narooie-Nejad et al. | 2015 | Iran | Asian | M = 25 / 28 F = 88/ 94 | 113 / 122 | 32.4 ± 8.9/ 30.8 ± 10.2 | PCR–RFLP | 7 |
| Al-Temaimi et al. | 2015 | Kuwait | Asian | M = 17/ 19 F = 33/ 31 | 50 / 50 | 33.4 ± 9.6/ 28.6 ± 7.9 | Taq-Man | 7 |
| Selma et al. | 2015 | Tunisia | African | M = 22/ 47 F = 38/ 67 | 60 / 114 | 35.8 ± 6.3 / 37 ± 9.3 | PCR–RFLP | 6 |
| Yamout et al. | 2016 | Lebanon | Asian | M = NR F=NR | 50 / 134 | 32.3 ± 12.7 / 35.2 ± 13 | PCR–RFLP | 6 |
| Luisa Agnello et al. | 2016 | Italy | European | M = 24 / 30 F = 80 / 42 | 104 / 75 | 39.6 ± 10.3/ 45.2 ± 9.36 | PCR–RFLP | 6 |
| Abdollahzadeh et al. | 2016 | Iran | Asian | M = 40 / 38 F = 120 / 112 | 160 / 150 | 35.9 ± 3 / 36.8 ± 1.8 | PCR–RFLP | 7 |
| Cierny et al. | 2016 | Slovakia | European | M = 66 / 74 F = 204 / 229 | 270 / 303 | 41.3 ± 10.8/ 38.7 ± 13.6 | PCR–RFLP | 8 |
| Terzi et al. | 2016 | Turkey | European | M = NR F=NR | 87 / 100 | 30.14 9.66/ NR | PCR–RFLP | 6 |
| Yucel et al. | 2017 | Turkey | European | M = NR F=NR | 26 / 81 | 33.7 ± 10.7 / 33.1 ± 8.5 | Taq-Man | 6 |
| Kamisli et al. | 2018 | Turkey | European | M = 46 / 58 F = 121 / 88 | 167 / 146 | 39.96 ± 9.4 / 33.81 ± 7.1 | Taq-Man | 8 |
| Sadeghi et al. | 2018 | Iran | Asian | M = 17/11 F = 63/39 | 80 / 50 | 18–60/ 18–60 | PCR–RFLP | 7 |
| Cakina et al.. | 2018 | Turkey | European | M = 19/22 F = 51/48 | 70 / 70 | 44.4 ± 11.2 / 38.2 ± 9.5 | PCR–RFLP | 7 |
| Křenek et al. | 2018 | Czech Republic | European | M = 80/49 F = 216/86 | 296 / 135 | 34–37 / NR | PCR–RFLP | 7 |
NR not reported, M male, F female, MS Multiple Sclerosis